Skip to content
PEPLUX

Semax + selank blend

Semax / Selank Injection

Illustrative PEPLUX product vial in a purple-lit studio
Product illustration

Product form

Subcutaneous injection

The process

Licensed provider review

Semax / Selank Injection cost

$229 per month

*If medically eligible.
Medication
Included
Clinician visit
Included
Baseline labs
Included
Lab retests
Included when ordered by your provider
Shipping
Included
Patient portal access
Included
Care-team chat support
Included

Considering more than one product?

  • Two products prescribed together: $349 per month
  • Three products prescribed together: $479 per month
Compare pricing

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

FDA status, checked on October 13, 2026

The Semax / Selank Injection combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

Order now

No compounding pathway today.

*If medically eligible.

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

PEPLUX is a telehealth platform, not a pharmacy or drug manufacturer. Medications are compounded and dispensed by independently licensed US compounding pharmacies.

Prescription products require an online evaluation with a licensed provider. Not all patients qualify.

States served: not yet confirmed. How state availability works

What is Semax / Selank Injection?

Semax combined with selank. The dispensing pharmacy must document the precise forms of both peptides before ordering is enabled.

Adults seeking a provider discussion about semax and selank together after reviewing their evidence limitations and risks. This listing does not establish that the combination has a benefit for any condition.

Key risks

  • The safety of semax and selank together has not been established. Side effects, interactions and longer-term risks of the mixture are not adequately characterized.
  • Both peptides raise concerns about immune reactions, including reactions to the peptide or impurities.
All risks and who should not use it

FDA status

FDA status for Semax / Selank Injection.

Rendered from our regulatory records, which cite FDA, Federal Register and label documents directly. Each record shows the date we last checked it.

No compounding pathway today.

The Semax / Selank Injection combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

An FDA advisory committee recommendation is not a listing. Nothing changes unless FDA publishes a final rule.

Semax (heptapeptide)

No compounding pathway today. An FDA advisory committee recommendation is not a listing.

Semax is not FDA-approved, and there is no pathway for a US pharmacy to compound it today. FDA removed it from its 503A Category 2 in April 2026 after the nominations were withdrawn, but removal is not a listing. FDA's Pharmacy Compounding Advisory Committee recommended it on July 24, 2026. A recommendation is not a listing: nothing changes unless FDA publishes a final rule.

Basis
FDA's 503A categories document of April 15, 2026 announced the removal of semax (heptapeptide) from Category 2, effective seven days later, because its nominations were withdrawn. It has no entry in FDA's current 503A or 503B category documents, it is not on the 503A bulks list (21 CFR 216.23) or the 503B bulks list, and it is not a component of an FDA-approved drug. FDA's safety page says compounded semax may pose a risk of immunogenicity and that FDA has no, or limited, safety-related information for the proposed routes of administration.
Checked on
October 13, 2026

Selank acetate (TP-7)

No compounding pathway today.

Selank is not FDA-approved, and there is no pathway for a US pharmacy to compound it today. FDA removed it from its 503A Category 2 on September 27, 2024, because the nominator had meant to nominate a different substance. FDA's Pharmacy Compounding Advisory Committee has not reviewed it, and nothing is pending.

Basis
FDA's 503A categories document of September 27, 2024 removed selank from Category 2 because the nominator meant to nominate a different bulk drug substance. It has no entry in FDA's current 503A or 503B category documents, it is not on the 503A bulks list (21 CFR 216.23) or the 503B bulks list, and it is not a component of an FDA-approved drug. FDA's safety page says compounded selank acetate may pose a risk of immunogenicity and that FDA lacks important information on any safety issues it raises in people.
Checked on
October 13, 2026

How it works

Semax / Selank Injection mechanism.

This product combines semax, a synthetic peptide built on a fragment of adrenocorticotropic hormone, with selank, a synthetic peptide derived from tuftsin. Laboratory studies of the individual substances do not establish how this combined formulation behaves in people. The exact chemical forms and route require confirmation before any treatment decision.

That describes what the molecule does in the body. It is not a claim about what it will do for you.

What the evidence supports

Semax / Selank Injection: evidence and limitations.

Published human studies of the individual peptides are limited. Results for either peptide alone cannot be transferred to a mixture, and PEPLUX has not verified clinical evidence establishing the safety or effectiveness of this combination.

Risks

Semax / Selank Injection risks and side effects.

  • The safety of semax and selank together has not been established. Side effects, interactions and longer-term risks of the mixture are not adequately characterized.
  • Both peptides raise concerns about immune reactions, including reactions to the peptide or impurities.
  • Nasal use can cause irritation inside the nose. Injectable use can cause pain, swelling or bruising and carries an infection risk if sterility fails.
  • Safety information is insufficient for use during pregnancy or breastfeeding or in people under 18. These groups should not use this product.
  • Seek urgent medical care for trouble breathing, swelling of the face or throat, or other signs of a serious allergic reaction.

This information is educational and is not medical advice. It does not establish a provider–patient relationship.

Clinical review

What your prescriber will consider.

These are decision factors a licensed provider weighs when deciding whether this product is appropriate for you. They are not instructions, and there is no dosing protocol on this page.

  • The exact identity of each ingredient, the intended formulation and route, and documentation from the prescriber and pharmacy before any treatment decision

  • All prescription medicines, supplements and other peptide products, because interactions between the ingredients are not established

  • Any prior allergic or immune reaction, current medical condition, pregnancy, breastfeeding or plans to conceive

  • Whether an established treatment should be considered first, and any applicable anti-doping rules

  • Medicines that act on the nervous system and any condition already receiving medical treatment

PEPLUX does not publish self-administration protocols. Dose, frequency and duration are set by your prescriber against your own history and reviewed over time.

Lot documents

What a certificate of analysis should cover.

When a pharmacy is named, each lot's certificate of analysis is expected to cover the tests below. No certificate exists or is published yet.

  • Potency
  • Sterility
  • Endotoxin
  • pH

Sport and anti-doping

WADA status.

  • Semax (heptapeptide): Not named on the WADA 2026 Prohibited List. Not named on the 2026 list. Whether the S0 class (substances with no government approval for human therapeutic use) reaches it has not been confirmed.
  • Selank acetate (TP-7): Not named on the WADA 2026 Prohibited List. Not named on the 2026 list. Whether the S0 class (substances with no government approval for human therapeutic use) reaches it has not been confirmed.

The list is revised every year. If you compete, check the current list and your federation’s own rules.

Straight answers

Common questions about Semax / Selank Injection.

What is the FDA status of Semax / Selank Injection?
No compounding pathway today. Semax (heptapeptide): Semax is not FDA-approved, and there is no pathway for a US pharmacy to compound it today. FDA removed it from its 503A Category 2 in April 2026 after the nominations were withdrawn, but removal is not a listing. FDA's Pharmacy Compounding Advisory Committee recommended it on July 24, 2026. A recommendation is not a listing: nothing changes unless FDA publishes a final rule. Checked against primary sources on October 13, 2026. Selank acetate (TP-7): Selank is not FDA-approved, and there is no pathway for a US pharmacy to compound it today. FDA removed it from its 503A Category 2 on September 27, 2024, because the nominator had meant to nominate a different substance. FDA's Pharmacy Compounding Advisory Committee has not reviewed it, and nothing is pending. Checked against primary sources on October 13, 2026.
Is compounded Semax / Selank Injection an approved drug?
No. Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality. The Semax / Selank Injection combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established. PEPLUX is a telehealth platform, not a pharmacy or drug manufacturer. Medications are compounded and dispensed by independently licensed US compounding pharmacies.
What does the evidence support for Semax / Selank Injection, and what does it not?
Published human studies of the individual peptides are limited. Results for either peptide alone cannot be transferred to a mixture, and PEPLUX has not verified clinical evidence establishing the safety or effectiveness of this combination.
What are the risks of Semax / Selank Injection?
The safety of semax and selank together has not been established. Side effects, interactions and longer-term risks of the mixture are not adequately characterized. The full list of side effects, and of who should not use Semax / Selank Injection, is in the risks section of this page. Your prescriber reviews your history before deciding whether it is appropriate for you.
Does Semax / Selank Injection require baseline labs?
Your prescriber determines whether baseline labs are needed before considering Semax / Selank Injection. Baseline labs are included in the price.
What does Semax / Selank Injection cost?
$229 per month. Medication: included. Clinician visit: included. Baseline labs: included. Lab retests: included when ordered by your provider. Shipping: included. Patient portal access: included. Care-team chat support: included. *If medically eligible.
Is Semax / Selank Injection prohibited in sport?
Semax (heptapeptide): Not named on the WADA 2026 Prohibited List. Not named on the 2026 list. Whether the S0 class (substances with no government approval for human therapeutic use) reaches it has not been confirmed. Selank acetate (TP-7): Not named on the WADA 2026 Prohibited List. Not named on the 2026 list. Whether the S0 class (substances with no government approval for human therapeutic use) reaches it has not been confirmed.
How is Semax / Selank Injection given?
Subcutaneous injection. Your prescriber decides whether it is appropriate for you and sets the regimen. PEPLUX does not publish dosing.

Next step

A licensed provider reviews every request.

The Semax / Selank Injection combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

Order now

No compounding pathway today.

*If medically eligible.

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

Also offered

Other products.

All productsFDA status tracker